Such therapies could provide a complementary approach to treat TNBC as well as other cancers where CDK7 inhibitors induce genome instability, such as the recently reported effects in SCLC and HCC (16, 24, 25, 90, 91). Here, CDK7 is linked to hepatocellular carcinoma.